Lukas Biomedical's earnings have been declining at an average annual rate of -19.9%, while the Biotechs industry saw earnings growing at 22.5% annually. Revenues have been growing at an average rate of 1.6% per year.
Key information
-19.86%
Earnings growth rate
-14.73%
EPS growth rate
Biotechs Industry Growth
12.22%
Revenue growth rate
1.58%
Return on equity
-48.13%
Net Margin
-54.14%
Last Earnings Update
30 Jun 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Lukas Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
TPEX:6814 Revenue, expenses and earnings (TWD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Jun 26
170
-92
108
81
31 Mar 26
175
-89
107
82
31 Dec 25
179
-86
106
83
30 Sep 25
180
-91
108
87
30 Jun 25
180
-96
109
92
31 Mar 25
185
-95
110
93
31 Dec 24
190
-94
111
95
30 Sep 24
202
-84
109
92
30 Jun 24
215
-73
108
90
31 Mar 24
223
-60
104
84
31 Dec 23
232
-47
100
77
30 Sep 23
222
-43
96
70
30 Jun 23
212
-38
91
63
31 Mar 23
198
-44
91
59
31 Dec 22
185
-50
90
56
30 Sep 22
176
-51
88
56
30 Jun 22
167
-52
86
57
31 Mar 22
162
-51
85
56
31 Dec 21
158
-49
84
55
30 Sep 21
164
-41
86
48
30 Jun 21
169
-32
88
42
31 Mar 21
175
-21
88
38
31 Dec 20
181
-11
88
35
30 Sep 20
176
-9
94
42
30 Jun 20
171
-7
100
48
31 Mar 20
162
-7
87
38
31 Dec 19
153
-7
74
29
31 Dec 18
132
-20
58
23
31 Dec 17
128
-11
50
18
Quality Earnings: 6814 is currently unprofitable.
Growing Profit Margin: 6814 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6814 is unprofitable, and losses have increased over the past 5 years at a rate of 19.9% per year.
Accelerating Growth: Unable to compare 6814's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6814 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.8%).
Return on Equity
High ROE: 6814 has a negative Return on Equity (-48.13%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/23 18:59
End of Day Share Price
2026/08/21 00:00
Earnings
2026/06/30
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lukas Biomedical Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.